Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study

Guillaume Cartron,Rémi Letestu,Caroline Dartigeas,Mira Tout,Beatrice Mahe,Anne-Laure Gagez,Emmanuelle Ferrant,Boris Guiu,Bruno Villemagne,Phan Letuan,Thérèse Aurran,Frédérique Orsini-Piocelle,Anne Banos,Pierre Feugier,Véronique Leblond,Sophie de Guibert,Olivier Tournilhac,Jehan Dupuis,Alain Delmer,Valérie Rouillé,David Ternant,Stéphane Leprêtre

Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study

2018

FCR regimen associating fludarabine, cyclophosphamide and rituximab (FCR) is still considered the gold standard for the first line treatment of medically fit patients with active B-cell chronic lymphocytic leukemia (CLL) and without del(17p) and/or TP53 mutations.[1][1] In addition, the persistence

Keywords:

Immunology
Chronic lymphocytic leukemia
Rituximab
Diabetes mellitus
Oncology
Cyclophosphamide/Rituximab
FCR Regimen
Fludarabine
Internal medicine
Medicine
Cyclophosphamide
Leukemia
first line treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations